SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

NCT07132242 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer With HER2 Positive

Interventions

DRUG: SHR-A1811 4.0mg/kg
DRUG: Pyrotinib 240mg
DRUG: SHR-A1811 4.8mg/kg
DRUG: Pyrotinib 320mg

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]